After a kidney transplant, patients receive drugs such as the new agent belatacept, to prevent rejection of the donor kidney. In a dossier assessment by IQWiG, treatment with belatacept was compared with cyclosporine A. According to the assessment, serious side effects are less frequent with belatacept in certain patients and these patients discontinue treatment due to side effects less often ...
